SELLAS Life Sciences Group, Inc. (SLS) 10-Year Financial Performance & Capital Metrics

SLS • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

AboutSELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.Show more

Revenue $0
EBITDA $0
Net Income -$31M +17.3%
EPS (Diluted) -0.05 +66.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -4147.88%
ROIC -
Debt/Equity 0.11
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 96 (top 4%)

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 100.0% in last year
✗Expensive at 248.3x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM19.63%

EPS CAGR

10Y-

5Y-

3Y-

TTM70.41%

ROCE

10Y Avg-423.06%

5Y Avg-774.72%

3Y Avg-1465.87%

Latest-2619.53%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.66B	105.24	701.60	14.76%	24.69%	25.55%	1.21%	0.01
TGTXTG Therapeutics, Inc.	4.88B	30.71	204.73	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.62B	27.80	2.39	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.48M	3.65	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	21.37M	1.04	-0.41	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	308.06M	14.06	-0.41			-94.52%		0.33
FATEFate Therapeutics, Inc.	121.12M	1.05	-0.64	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	121.95M	6.66	-0.71	-0.55%	-87.43%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	1.9M	7.6M	1M	0	0
Revenue Growth %	-1%	-	-	-	-	-	3%	-0.87%	-1%	-
Cost of Goods Sold+	355K	3K	0	0	0	0	200K	100K	0	0
COGS % of Revenue	-	-	-	-	-	-	0.03%	0.1%	-	-
Gross Profit+	-355K	-3K	0	0	0	1.9M	7.4M	900K	0	0
Gross Margin %	-	-	-	-	-	1%	0.97%	0.9%	-	-
Gross Profit Growth %	-1.04%	0.99%	1%	-	-	-	2.89%	-0.88%	-1%	-
Operating Expenses+	33.87M	31.87M	21.16M	31.59M	20.04M	18.88M	32.69M	42.85M	37.87M	31.51M
OpEx % of Revenue	-	-	-	-	-	9.94%	4.3%	42.85%	-	-
Selling, General & Admin	10.25M	12.01M	15.09M	12.77M	9.92M	9.6M	11.32M	12.58M	13.86M	12.42M
SG&A % of Revenue	-	-	-	-	-	5.05%	1.49%	12.58%	-	-
Research & Development	23.61M	19.86M	6.07M	18.32M	10.12M	9.28M	21.37M	30.27M	24.01M	19.1M
R&D % of Revenue	-	-	-	-	-	4.89%	2.81%	30.27%	-	-
Other Operating Expenses	0	0	0	-3.03M	0	0	0	0	0	0
Operating Income+	-34.22M	-15.99M	-15.71M	-31.59M	-20.04M	-16.98M	-25.29M	-41.95M	-37.87M	-31.51M
Operating Margin %	-	-	-	-	-	-8.94%	-3.33%	-41.95%	-	-
Operating Income Growth %	0.07%	0.53%	0.02%	-1.01%	0.37%	0.15%	-0.49%	-0.66%	0.1%	0.17%
EBITDA+	-33.87M	-15.98M	-15.71M	-9.55M	-2.83M	-16.61M	-24.02M	-41.49M	0	0
EBITDA Margin %	-	-	-	-	-	-8.74%	-3.16%	-41.49%	-	-
EBITDA Growth %	0.06%	0.53%	0.02%	0.39%	0.7%	-4.86%	-0.45%	-0.73%	1%	-
D&A (Non-Cash Add-back)	355K	3K	3K	22.04M	17.21M	377K	1.27M	457K	37.87M	31.51M
EBIT	-37.83M	-15.99M	-23.04M	-28.78M	-17.21M	-16.77M	-19.59M	-31.95M	-37.34M	-30.88M
Net Interest Income+	0	0	0	0	0	26K	6K	317K	525K	632K
Interest Income	0	0	0	0	118K	26K	6K	317K	525K	632K
Interest Expense	760K	3.51M	462K	266K	118K	0	0	0	0	0
Other Income/Expense	-4.37M	5.13M	-7.79M	2.54M	668K	208K	4.36M	649K	529K	632K
Pretax Income+	-38.59M	-17.68M	-23.5M	-29.05M	-19.37M	-16.77M	-20.94M	-41.3M	-37.34M	-30.88M
Pretax Margin %	-	-	-	-	-	-8.83%	-2.75%	-41.3%	-	-
Income Tax+	365K	243K	253K	-1.38M	-81K	-17K	-237K	0	0	0
Effective Tax Rate %	1.66%	1.33%	1.01%	0.95%	1%	1%	0.99%	1%	1%	1%
Net Income+	-63.9M	-23.55M	-23.75M	-27.67M	-19.29M	-16.76M	-20.7M	-41.3M	-37.34M	-30.88M
Net Margin %	-	-	-	-	-	-8.82%	-2.72%	-41.3%	-	-
Net Income Growth %	-0.75%	0.63%	-0.01%	-0.16%	0.3%	0.13%	-0.24%	-1%	0.1%	0.17%
Net Income (Continuing)	-38.96M	-17.68M	-23.75M	-27.67M	-19.29M	-16.76M	-20.7M	-41.3M	-37.34M	-30.88M
Discontinued Operations	-20.4M	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1372.02	-394.12	-56.39	-11.76	-0.84	-2.11	-1.34	-2.13	-0.15	-0.05
EPS Growth %	-0.34%	0.71%	0.86%	0.79%	0.93%	-1.51%	0.36%	-0.59%	0.93%	0.66%
EPS (Basic)	-1372.03	-394.12	-56.39	-11.76	-0.84	-2.11	-1.34	-2.13	-0.15	-0.05
Diluted Shares Outstanding	46.58K	59.75K	46.81K	2.35M	23.03M	7.98M	15.48M	19.4M	249.99M	612.02M
Basic Shares Outstanding	46.57K	59.75K	45K	2.35M	23.03M	7.98M	15.48M	19.4M	249.99M	612.02M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	53.62M	37.5M	13.09M	5.84M	8.24M	36.92M	23.04M	17.76M	3.17M	16.33M
Cash & Short-Term Investments	29.73M	18.08M	2.32M	5.34M	7.28M	35.3M	21.45M	17.13M	2.53M	13.89M
Cash Only	29.73M	18.08M	2.32M	5.34M	7.28M	35.3M	21.45M	17.13M	2.53M	13.89M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	308K	1.13M	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	216.69	-	-	-	-
Inventory	-19.51M	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	22.49M	85K	10.43M	291K	184K	130K	27K	330K	100K	100K
Total Non-Current Assets+	28.52M	28.31M	20.44M	11.08M	8.37M	9.12M	3.38M	3.19M	3.05M	3.31M
Property, Plant & Equipment	335K	199K	0	0	217K	896K	723K	874K	858K	925K
Fixed Asset Turnover	-	-	-	-	-	2.12x	10.51x	1.14x	-	-
Goodwill	5.9M	5.9M	1.91M	1.91M	1.91M	1.91M	1.91M	1.91M	1.91M	1.91M
Intangible Assets	22.12M	22.12M	17.6M	8.5M	5.7M	5.7M	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	-184K	0	0
Other Non-Current Assets	171K	96K	925K	-765K	536K	614K	594K	399K	275K	466K
Total Assets+	82.14M	65.81M	33.53M	16.91M	16.61M	46.05M	26.43M	20.94M	6.22M	19.43M
Asset Turnover	-	-	-	-	-	0.04x	0.29x	0.05x	-	-
Asset Growth %	0.02%	-0.2%	-0.49%	-0.5%	-0.02%	1.77%	-0.43%	-0.21%	-0.7%	2.12%
Total Current Liabilities+	57.07M	30.4M	24.57M	5.97M	5.29M	12.34M	4.98M	15.52M	13.73M	9.51M
Accounts Payable	1.6M	0	11.69M	3.75M	3.9M	4.66M	2.14M	3.36M	5.64M	3.5M
Days Payables Outstanding	1.64K	-	-	-	-	-	3.91K	12.25K	-	-
Short-Term Debt	4.74M	1.71M	8.38M	0	0	0	198K	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	0	0	1000K	0	0	0	0
Other Current Liabilities	24.2M	2.01M	1.49M	8K	606K	1.01M	1.65M	5.5M	1.53M	1.82M
Current Ratio	0.94x	1.23x	0.53x	0.98x	1.56x	2.99x	4.63x	1.14x	0.23x	1.72x
Quick Ratio	1.28x	1.23x	0.53x	0.98x	1.56x	2.99x	4.63x	1.14x	0.23x	1.72x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	11.56M	6.76M	6.89M	5.7M	5.23M	5.75M	1.1M	577K	460K	457K
Long-Term Debt	0	5.66M	2.61M	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	825K	610K	573K	460K	457K
Deferred Tax Liabilities	5.42M	5.66M	1.67M	357K	262K	239K	152K	184K	0	0
Other Non-Current Liabilities	6.14M	-5.66M	2.6M	5.34M	4.96M	4.69M	336K	4K	0	0
Total Liabilities	68.63M	37.15M	31.46M	11.67M	10.52M	18.09M	6.08M	16.09M	14.2M	9.97M
Total Debt+	4.74M	16.4M	10.99M	0	217K	991K	808K	945K	906K	1M
Net Debt	-24.99M	-1.69M	8.67M	-5.34M	-7.06M	-34.31M	-20.65M	-16.18M	-1.62M	-12.88M
Debt / Equity	0.35x	0.57x	5.31x	-	0.04x	0.04x	0.04x	0.19x	-	0.11x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-45.03x	-4.56x	-34.01x	-118.76x	-169.84x	-	-	-	-	-
Total Equity+	13.51M	28.66M	2.07M	5.25M	6.09M	27.96M	20.35M	4.85M	-7.98M	9.46M
Equity Growth %	-0.64%	1.12%	-0.93%	1.53%	0.16%	3.59%	-0.27%	-0.76%	-2.64%	2.19%
Book Value per Share	290.13	479.61	44.22	2.23	0.26	3.51	1.31	0.25	-0.03	0.02
Total Shareholders' Equity	13.51M	28.66M	2.07M	5.25M	6.09M	27.96M	20.35M	4.85M	-7.98M	9.46M
Common Stock	15K	15K	1K	2K	1K	1K	2K	2K	3K	7K
Retained Earnings	-279.38M	-302.93M	-54.19M	-81.86M	-101.15M	-117.9M	-138.6M	-179.9M	-217.24M	-248.13M
Treasury Stock	-3.85M	-3.85M	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-48.16M	-44.91M	-10.99M	-30.42M	-17.64M	-10.42M	-26.02M	-23.81M	-31.41M	-35.4M
Operating CF Margin %	-	-	-	-	-	-5.48%	-3.42%	-23.81%	-	-
Operating CF Growth %	-0.12%	0.07%	0.76%	-1.77%	0.42%	0.41%	-1.5%	0.09%	-0.32%	-0.13%
Net Income	-38.96M	-11.1M	-23.75M	-27.67M	-19.29M	-16.76M	-20.7M	-41.3M	-37.34M	-30.88M
Depreciation & Amortization	355K	142K	0	3.76M	1.7M	282K	5.68M	457K	0	0
Stock-Based Compensation	1.93M	2.26M	3.17M	395K	573K	578K	1.01M	1.73M	1.39M	1.56M
Deferred Taxes	365K	243K	0	-1.32M	-95K	-23K	-239K	-457K	0	0
Other Non-Cash Items	-31.73M	-11.55M	3.53M	4.42M	586K	-87K	-4.16M	10.13M	1.2M	561K
Working Capital Changes	19.87M	-24.91M	6.07M	-10.01M	-1.11M	5.59M	-7.62M	5.64M	3.35M	-6.65M
Change in Receivables	0	21.7M	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	-289K	-757K	8.37M	-7.94M	12K	-836K	-2.51M	1.21M	2.3M	-2.14M
Cash from Investing+	10.39M	-1.06M	1.81M	0	0	0	0	-4.5M	-5.5M	0
Capital Expenditures	-153K	-6K	0	0	0	0	0	-4.5M	-5.5M	0
CapEx % of Revenue	-	-	-	-	-	-	-	4.5%	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	10.55M	-1.05M	0	0	0	0	0	0	0	0
Cash from Financing+	43.84M	34.32M	5.53M	23.12M	19.57M	38.44M	12.07M	24.08M	22.32M	46.76M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	-675K	-487K	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	31K	0	0	0	3.6M	8.84M	3.07M	85K	90K	594K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-48.31M	-44.92M	-10.99M	-30.42M	-17.64M	-10.42M	-26.02M	-28.31M	-36.91M	-35.4M
FCF Margin %	-	-	-	-	-	-5.48%	-3.42%	-28.31%	-	-
FCF Growth %	0%	0.07%	0.76%	-1.77%	0.42%	0.41%	-1.5%	-0.09%	-0.3%	0.04%
FCF per Share	-1037.32	-751.80	-234.77	-12.92	-0.77	-1.31	-1.68	-1.46	-0.15	-0.06
FCF Conversion (FCF/Net Income)	0.75x	1.91x	0.46x	1.10x	0.91x	0.62x	1.26x	0.58x	0.84x	1.15x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-252.72%	-111.69%	-154.61%	-756.53%	-340.31%	-98.41%	-85.7%	-327.81%	-	-4147.88%
Return on Invested Capital (ROIC)	-496.76%	-154.79%	-62.51%	-445.04%	-	-	-	-	-	-
Gross Margin	-	-	-	-	-	100%	97.37%	90%	-	-
Net Margin	-	-	-	-	-	-881.95%	-272.36%	-4130.1%	-	-
Debt / Equity	0.35x	0.57x	5.31x	-	0.04x	0.04x	0.04x	0.19x	-	0.11x
Interest Coverage	-45.03x	-4.56x	-34.01x	-118.76x	-169.84x	-	-	-	-	-
FCF Conversion	0.75x	1.91x	0.46x	1.10x	0.91x	0.62x	1.26x	0.58x	0.84x	1.15x
Revenue Growth	-100%	-	-	-	-	-	300%	-86.84%	-100%	-

Frequently Asked Questions

Growth & Financials

SELLAS Life Sciences Group, Inc. (SLS) grew revenue by 0.0% over the past year. Growth has been modest.

SELLAS Life Sciences Group, Inc. (SLS) reported a net loss of $25.9M for fiscal year 2024.

Dividend & Returns

SELLAS Life Sciences Group, Inc. (SLS) has a return on equity (ROE) of -4147.9%. Negative ROE indicates the company is unprofitable.

SELLAS Life Sciences Group, Inc. (SLS) had negative free cash flow of $30.6M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

SELLAS Life Sciences Group, Inc. (SLS) 10-Year Financial Performance & Capital Metrics

SLS • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

Revenue $0
EBITDA $0
Net Income -$31M +17.3%
EPS (Diluted) -0.05 +66.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -4147.88%
ROIC -
Debt/Equity 0.11
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 96 (top 4%)

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 100.0% in last year
✗Expensive at 248.3x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM19.63%

EPS CAGR

10Y-

5Y-

3Y-

TTM70.41%

ROCE

10Y Avg-423.06%

5Y Avg-774.72%

3Y Avg-1465.87%

Latest-2619.53%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.66B	105.24	701.60	14.76%	24.69%	25.55%	1.21%	0.01
TGTXTG Therapeutics, Inc.	4.88B	30.71	204.73	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.62B	27.80	2.39	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.48M	3.65	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	21.37M	1.04	-0.41	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	308.06M	14.06	-0.41			-94.52%		0.33
FATEFate Therapeutics, Inc.	121.12M	1.05	-0.64	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	121.95M	6.66	-0.71	-0.55%	-87.43%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	1.9M	7.6M	1M	0	0
Revenue Growth %	-1%	-	-	-	-	-	3%	-0.87%	-1%	-
Cost of Goods Sold+	355K	3K	0	0	0	0	200K	100K	0	0
COGS % of Revenue	-	-	-	-	-	-	0.03%	0.1%	-	-
Gross Profit+	-355K	-3K	0	0	0	1.9M	7.4M	900K	0	0
Gross Margin %	-	-	-	-	-	1%	0.97%	0.9%	-	-
Gross Profit Growth %	-1.04%	0.99%	1%	-	-	-	2.89%	-0.88%	-1%	-
Operating Expenses+	33.87M	31.87M	21.16M	31.59M	20.04M	18.88M	32.69M	42.85M	37.87M	31.51M
OpEx % of Revenue	-	-	-	-	-	9.94%	4.3%	42.85%	-	-
Selling, General & Admin	10.25M	12.01M	15.09M	12.77M	9.92M	9.6M	11.32M	12.58M	13.86M	12.42M
SG&A % of Revenue	-	-	-	-	-	5.05%	1.49%	12.58%	-	-
Research & Development	23.61M	19.86M	6.07M	18.32M	10.12M	9.28M	21.37M	30.27M	24.01M	19.1M
R&D % of Revenue	-	-	-	-	-	4.89%	2.81%	30.27%	-	-
Other Operating Expenses	0	0	0	-3.03M	0	0	0	0	0	0
Operating Income+	-34.22M	-15.99M	-15.71M	-31.59M	-20.04M	-16.98M	-25.29M	-41.95M	-37.87M	-31.51M
Operating Margin %	-	-	-	-	-	-8.94%	-3.33%	-41.95%	-	-
Operating Income Growth %	0.07%	0.53%	0.02%	-1.01%	0.37%	0.15%	-0.49%	-0.66%	0.1%	0.17%
EBITDA+	-33.87M	-15.98M	-15.71M	-9.55M	-2.83M	-16.61M	-24.02M	-41.49M	0	0
EBITDA Margin %	-	-	-	-	-	-8.74%	-3.16%	-41.49%	-	-
EBITDA Growth %	0.06%	0.53%	0.02%	0.39%	0.7%	-4.86%	-0.45%	-0.73%	1%	-
D&A (Non-Cash Add-back)	355K	3K	3K	22.04M	17.21M	377K	1.27M	457K	37.87M	31.51M
EBIT	-37.83M	-15.99M	-23.04M	-28.78M	-17.21M	-16.77M	-19.59M	-31.95M	-37.34M	-30.88M
Net Interest Income+	0	0	0	0	0	26K	6K	317K	525K	632K
Interest Income	0	0	0	0	118K	26K	6K	317K	525K	632K
Interest Expense	760K	3.51M	462K	266K	118K	0	0	0	0	0
Other Income/Expense	-4.37M	5.13M	-7.79M	2.54M	668K	208K	4.36M	649K	529K	632K
Pretax Income+	-38.59M	-17.68M	-23.5M	-29.05M	-19.37M	-16.77M	-20.94M	-41.3M	-37.34M	-30.88M
Pretax Margin %	-	-	-	-	-	-8.83%	-2.75%	-41.3%	-	-
Income Tax+	365K	243K	253K	-1.38M	-81K	-17K	-237K	0	0	0
Effective Tax Rate %	1.66%	1.33%	1.01%	0.95%	1%	1%	0.99%	1%	1%	1%
Net Income+	-63.9M	-23.55M	-23.75M	-27.67M	-19.29M	-16.76M	-20.7M	-41.3M	-37.34M	-30.88M
Net Margin %	-	-	-	-	-	-8.82%	-2.72%	-41.3%	-	-
Net Income Growth %	-0.75%	0.63%	-0.01%	-0.16%	0.3%	0.13%	-0.24%	-1%	0.1%	0.17%
Net Income (Continuing)	-38.96M	-17.68M	-23.75M	-27.67M	-19.29M	-16.76M	-20.7M	-41.3M	-37.34M	-30.88M
Discontinued Operations	-20.4M	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1372.02	-394.12	-56.39	-11.76	-0.84	-2.11	-1.34	-2.13	-0.15	-0.05
EPS Growth %	-0.34%	0.71%	0.86%	0.79%	0.93%	-1.51%	0.36%	-0.59%	0.93%	0.66%
EPS (Basic)	-1372.03	-394.12	-56.39	-11.76	-0.84	-2.11	-1.34	-2.13	-0.15	-0.05
Diluted Shares Outstanding	46.58K	59.75K	46.81K	2.35M	23.03M	7.98M	15.48M	19.4M	249.99M	612.02M
Basic Shares Outstanding	46.57K	59.75K	45K	2.35M	23.03M	7.98M	15.48M	19.4M	249.99M	612.02M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	53.62M	37.5M	13.09M	5.84M	8.24M	36.92M	23.04M	17.76M	3.17M	16.33M
Cash & Short-Term Investments	29.73M	18.08M	2.32M	5.34M	7.28M	35.3M	21.45M	17.13M	2.53M	13.89M
Cash Only	29.73M	18.08M	2.32M	5.34M	7.28M	35.3M	21.45M	17.13M	2.53M	13.89M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	308K	1.13M	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	216.69	-	-	-	-
Inventory	-19.51M	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	22.49M	85K	10.43M	291K	184K	130K	27K	330K	100K	100K
Total Non-Current Assets+	28.52M	28.31M	20.44M	11.08M	8.37M	9.12M	3.38M	3.19M	3.05M	3.31M
Property, Plant & Equipment	335K	199K	0	0	217K	896K	723K	874K	858K	925K
Fixed Asset Turnover	-	-	-	-	-	2.12x	10.51x	1.14x	-	-
Goodwill	5.9M	5.9M	1.91M	1.91M	1.91M	1.91M	1.91M	1.91M	1.91M	1.91M
Intangible Assets	22.12M	22.12M	17.6M	8.5M	5.7M	5.7M	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	-184K	0	0
Other Non-Current Assets	171K	96K	925K	-765K	536K	614K	594K	399K	275K	466K
Total Assets+	82.14M	65.81M	33.53M	16.91M	16.61M	46.05M	26.43M	20.94M	6.22M	19.43M
Asset Turnover	-	-	-	-	-	0.04x	0.29x	0.05x	-	-
Asset Growth %	0.02%	-0.2%	-0.49%	-0.5%	-0.02%	1.77%	-0.43%	-0.21%	-0.7%	2.12%
Total Current Liabilities+	57.07M	30.4M	24.57M	5.97M	5.29M	12.34M	4.98M	15.52M	13.73M	9.51M
Accounts Payable	1.6M	0	11.69M	3.75M	3.9M	4.66M	2.14M	3.36M	5.64M	3.5M
Days Payables Outstanding	1.64K	-	-	-	-	-	3.91K	12.25K	-	-
Short-Term Debt	4.74M	1.71M	8.38M	0	0	0	198K	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	0	0	1000K	0	0	0	0
Other Current Liabilities	24.2M	2.01M	1.49M	8K	606K	1.01M	1.65M	5.5M	1.53M	1.82M
Current Ratio	0.94x	1.23x	0.53x	0.98x	1.56x	2.99x	4.63x	1.14x	0.23x	1.72x
Quick Ratio	1.28x	1.23x	0.53x	0.98x	1.56x	2.99x	4.63x	1.14x	0.23x	1.72x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	11.56M	6.76M	6.89M	5.7M	5.23M	5.75M	1.1M	577K	460K	457K
Long-Term Debt	0	5.66M	2.61M	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	825K	610K	573K	460K	457K
Deferred Tax Liabilities	5.42M	5.66M	1.67M	357K	262K	239K	152K	184K	0	0
Other Non-Current Liabilities	6.14M	-5.66M	2.6M	5.34M	4.96M	4.69M	336K	4K	0	0
Total Liabilities	68.63M	37.15M	31.46M	11.67M	10.52M	18.09M	6.08M	16.09M	14.2M	9.97M
Total Debt+	4.74M	16.4M	10.99M	0	217K	991K	808K	945K	906K	1M
Net Debt	-24.99M	-1.69M	8.67M	-5.34M	-7.06M	-34.31M	-20.65M	-16.18M	-1.62M	-12.88M
Debt / Equity	0.35x	0.57x	5.31x	-	0.04x	0.04x	0.04x	0.19x	-	0.11x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-45.03x	-4.56x	-34.01x	-118.76x	-169.84x	-	-	-	-	-
Total Equity+	13.51M	28.66M	2.07M	5.25M	6.09M	27.96M	20.35M	4.85M	-7.98M	9.46M
Equity Growth %	-0.64%	1.12%	-0.93%	1.53%	0.16%	3.59%	-0.27%	-0.76%	-2.64%	2.19%
Book Value per Share	290.13	479.61	44.22	2.23	0.26	3.51	1.31	0.25	-0.03	0.02
Total Shareholders' Equity	13.51M	28.66M	2.07M	5.25M	6.09M	27.96M	20.35M	4.85M	-7.98M	9.46M
Common Stock	15K	15K	1K	2K	1K	1K	2K	2K	3K	7K
Retained Earnings	-279.38M	-302.93M	-54.19M	-81.86M	-101.15M	-117.9M	-138.6M	-179.9M	-217.24M	-248.13M
Treasury Stock	-3.85M	-3.85M	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-48.16M	-44.91M	-10.99M	-30.42M	-17.64M	-10.42M	-26.02M	-23.81M	-31.41M	-35.4M
Operating CF Margin %	-	-	-	-	-	-5.48%	-3.42%	-23.81%	-	-
Operating CF Growth %	-0.12%	0.07%	0.76%	-1.77%	0.42%	0.41%	-1.5%	0.09%	-0.32%	-0.13%
Net Income	-38.96M	-11.1M	-23.75M	-27.67M	-19.29M	-16.76M	-20.7M	-41.3M	-37.34M	-30.88M
Depreciation & Amortization	355K	142K	0	3.76M	1.7M	282K	5.68M	457K	0	0
Stock-Based Compensation	1.93M	2.26M	3.17M	395K	573K	578K	1.01M	1.73M	1.39M	1.56M
Deferred Taxes	365K	243K	0	-1.32M	-95K	-23K	-239K	-457K	0	0
Other Non-Cash Items	-31.73M	-11.55M	3.53M	4.42M	586K	-87K	-4.16M	10.13M	1.2M	561K
Working Capital Changes	19.87M	-24.91M	6.07M	-10.01M	-1.11M	5.59M	-7.62M	5.64M	3.35M	-6.65M
Change in Receivables	0	21.7M	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	-289K	-757K	8.37M	-7.94M	12K	-836K	-2.51M	1.21M	2.3M	-2.14M
Cash from Investing+	10.39M	-1.06M	1.81M	0	0	0	0	-4.5M	-5.5M	0
Capital Expenditures	-153K	-6K	0	0	0	0	0	-4.5M	-5.5M	0
CapEx % of Revenue	-	-	-	-	-	-	-	4.5%	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	10.55M	-1.05M	0	0	0	0	0	0	0	0
Cash from Financing+	43.84M	34.32M	5.53M	23.12M	19.57M	38.44M	12.07M	24.08M	22.32M	46.76M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	-675K	-487K	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	31K	0	0	0	3.6M	8.84M	3.07M	85K	90K	594K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-48.31M	-44.92M	-10.99M	-30.42M	-17.64M	-10.42M	-26.02M	-28.31M	-36.91M	-35.4M
FCF Margin %	-	-	-	-	-	-5.48%	-3.42%	-28.31%	-	-
FCF Growth %	0%	0.07%	0.76%	-1.77%	0.42%	0.41%	-1.5%	-0.09%	-0.3%	0.04%
FCF per Share	-1037.32	-751.80	-234.77	-12.92	-0.77	-1.31	-1.68	-1.46	-0.15	-0.06
FCF Conversion (FCF/Net Income)	0.75x	1.91x	0.46x	1.10x	0.91x	0.62x	1.26x	0.58x	0.84x	1.15x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-252.72%	-111.69%	-154.61%	-756.53%	-340.31%	-98.41%	-85.7%	-327.81%	-	-4147.88%
Return on Invested Capital (ROIC)	-496.76%	-154.79%	-62.51%	-445.04%	-	-	-	-	-	-
Gross Margin	-	-	-	-	-	100%	97.37%	90%	-	-
Net Margin	-	-	-	-	-	-881.95%	-272.36%	-4130.1%	-	-
Debt / Equity	0.35x	0.57x	5.31x	-	0.04x	0.04x	0.04x	0.19x	-	0.11x
Interest Coverage	-45.03x	-4.56x	-34.01x	-118.76x	-169.84x	-	-	-	-	-
FCF Conversion	0.75x	1.91x	0.46x	1.10x	0.91x	0.62x	1.26x	0.58x	0.84x	1.15x
Revenue Growth	-100%	-	-	-	-	-	300%	-86.84%	-100%	-

Frequently Asked Questions

Growth & Financials

SELLAS Life Sciences Group, Inc. (SLS) grew revenue by 0.0% over the past year. Growth has been modest.

SELLAS Life Sciences Group, Inc. (SLS) reported a net loss of $25.9M for fiscal year 2024.

Dividend & Returns

SELLAS Life Sciences Group, Inc. (SLS) has a return on equity (ROE) of -4147.9%. Negative ROE indicates the company is unprofitable.

SELLAS Life Sciences Group, Inc. (SLS) had negative free cash flow of $30.6M in fiscal year 2024, likely due to heavy capital investments.